drugset / Trial / NCT01911468

Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin

NCT01911468

Phase 4 Completed 36 enrolled University Medical Centre Ljubljana
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to determine whether combined treatment with liraglutide and metformin is more effective than liraglutide or metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome (PCOS) who had been previously poor responders regarding weight reduction on metformin monotherapy. We anticipated greater changes in body weight in patients on combined treatment than in those on monotherapy with liraglutide or metformin.

Timeline

Start
2011-11
Primary completion
2012-10
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liraglutide Peptide 1.2 mg Subcutaneous
Comparator Metformin Small molecule 1000 mg Oral